

Research

Open Access

Antibiotic resistance as a global threat: Evidence from China, Kuwait and the United States

Ruifang Zhang¹, Karen Eggleston^{*2}, Vincent Rotimi³ and Richard J Zeckhauser⁴

Address: ¹Goldman Sachs International, Global Investment Research, London, UK, ²Tufts University Economics Department, Medford, MA 02155, USA, ³Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait and ⁴Harvard University Kennedy School of Government, Cambridge, MA, USA

Email: Ruifang Zhang - ruifang.zhang@gs.com; Karen Eggleston^{*} - karen.eggleston@tufts.edu; Vincent Rotimi - vincent@HSC.EDU.KW; Richard J Zeckhauser - richard_zeckhauser@harvard.edu

^{*} Corresponding author

Published: 07 April 2006

Received: 04 September 2005

Globalization and Health 2006, 2:6 doi:10.1186/1744-8603-2-6

Accepted: 07 April 2006

This article is available from: <http://www.globalizationandhealth.com/content/2/1/6>

© 2006 Zhang et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Antimicrobial resistance is an under-appreciated threat to public health in nations around the globe. With globalization booming, it is important to understand international patterns of resistance. If countries already experience similar patterns of resistance, it may be too late to worry about international spread. If large countries or groups of countries that are likely to leap ahead in their integration with the rest of the world – China being the standout case – have high and distinctive patterns of resistance, then a coordinated response could substantially help to control the spread of resistance. The literature to date provides only limited evidence on these issues.

Methods: We study the recent patterns of antibiotic resistance in three geographically separated, and culturally and economically distinct countries – China, Kuwait and the United States – to gauge the range and depth of this global health threat, and its potential for growth as globalization expands. Our primary measures are the prevalence of resistance of specific bacteria to specific antibiotics. We also propose and illustrate methods for aggregating specific "bug-drug" data. We use these aggregate measures to summarize the resistance pattern for each country and to study the extent of correlation between countries' patterns of drug resistance.

Results: We find that China has the highest level of antibiotic resistance, followed by Kuwait and the U.S. In a study of resistance patterns of several most common bacteria in China in 1999 and 2001, the mean prevalence of resistance among hospital-acquired infections was as high as 41% (with a range from 23% to 77%) and that among community-acquired infections was 26% (with a range from 15% to 39%). China also has the most rapid growth rate of resistance (22% average growth in a study spanning 1994 to 2000). Kuwait is second (17% average growth in a period from 1999 to 2003), and the U.S. the lowest (6% from 1999 to 2002). Patterns of resistance across the three countries are not highly correlated; the most correlated were China and Kuwait, followed by Kuwait and the U.S., and the least correlated pair was China and the U.S.

Conclusion: Antimicrobial resistance is a serious and growing problem in all three countries. To date, there is not strong international convergence in the countries' resistance patterns. This finding may change with the greater international travel that will accompany globalization. Future research on the determinants of drug resistance patterns, and their international convergence or divergence, should be a priority.

In 1942, the first U.S. patient with streptococcal infection was miraculously cured with a small dose of penicillin. Sixty years later, penicillin-resistant *Streptococcus* is widespread. Such antimicrobial resistance threatens the health of many throughout the world, since both old and new infectious diseases remain a formidable public health threat.

Among the issues that merit further scrutiny for understanding the possible spread of antimicrobial resistance, few are as salient as the impact of globalization. Clearly the movement of people and goods around the globe contributes to transmission of disease [1,2]. To what extent drug resistance and globalization are similarly related remains unclear. The breakout of Severe Acute Respiratory Syndrome (SARS) in the spring of 2003 illustrates how an infectious disease with limited therapeutic options can spread rapidly across national borders. With globalization booming, it is important to understand international patterns of resistance. If countries already experience similar patterns of resistance, it may be too late to worry about international spread. If large countries or groups of countries that are likely to leap ahead in their integration with the rest of the world – China being the standout case – have high and distinctive patterns of resistance, then a coordinated response could help substantially to control the spread of resistance. The literature to date provides only limited evidence on these issues.

We study the pattern of antibiotic resistance in specific countries to gauge the range and depth of this global health threat. China and the U.S. stand out as good choices for study. Both are world economic powerhouses increasingly responding to the forces of economic globalization. In addition, both are major consumers of antibiotics, with the U.S. also being a leading source of new antibiotics. On the other hand, it would also be interesting to compare patterns of antibiotic resistance in smaller countries that stand relatively distant from these two. Accordingly, we compare the experiences of the U.S. and China with new data on the resistance experience of Kuwait.

The first section gives brief background on antibiotic resistance and its costs. We then turn to a detailed comparison of surveillance data from China, Kuwait, and the U.S. We conclude with a plea for more research and attention on this critical issue for health and globalization.

Background: The challenge of antimicrobial resistance

According to laws of Darwinian evolution, antimicrobial use creates a selection pressure on microorganisms: weak ones are killed, but stronger ones might adapt and survive. When pathogenic microorganisms can multiply beyond

some critical mass in the face of invading antimicrobials, treatment outcome is compromised; this phenomenon is referred as antimicrobial resistance (AMR) [3-9]. This paper focuses on antibiotic resistance, a major form of AMR.

Resistance mechanisms may develop over months or years [6]. Once established, a single resistance mechanism can often allow a bacterium to resist multiple drugs. It remains unclear whether resistance is reversible, and thus whether drug effectiveness is a renewable or non-renewable resource [10-15]. Drug resistance raises the cost of treatment for infectious diseases, sometimes manifold, as well as increasing morbidity and mortality from such diseases [16-23].

The greatest long-term threat of AMR is that resistant strains erode drug efficacy over time. The development of drug-resistant *Staphylococci aureus* (SAU) well illustrates the see-saw battle between pathogens and drugs. SAU is a bacterium that harmlessly lives in the human body but can cause infections on wounds or lesions. After the clinical application of penicillin in the 1940s, SAU soon adapted to the treatment mechanism of penicillin, and by the 1950s, almost half of SAU strains had become resistant to penicillin. A new antibiotic, methicillin, was developed in the 1960s. Yet by the late 1970s, methicillin-resistant SAU, i.e. MRSA, again became widespread. Today MRSA has become a major infectious culprit that can only be effectively treated with vancomycin, one of the few last killers of superbugs. Unfortunately, in 1996, a Japanese hospital reported the first case of vancomycin-resistant SAU (VRSA) during surgery on a four-month-old boy. The U.S., France and Hong Kong subsequently all reported VRSA incidents. A few years later in 2000, linezolid was launched as a new antibiotic to combat both MRSA and VRSA. But only one year later, Boston researchers reported the first case of linezolid-resistant MRSA in an 85-year-old man undergoing peritoneal dialysis. After failing to contain his MRSA by linezolid, researchers tried five antibiotics (ampicillin, azithromycin, gentamicin, levofloxacin, and quinupristin-dalfopristin) but the unlucky man eventually died from the uncontrollable infection [24].

Resistant pathogens within a hospital or specific community can spread to a nation at large or across national boundaries. Thus, for example, rapidly increasing travel and migration within China probably contributes to the growth of that nation's resistance problem. It may also spur the spread of China's resistance problems overseas as globalization greatly increases travel from and to that nation (see Figure 1).

Methods


We collected data on drug resistance in China, the U.S. and Kuwait, drawing from published studies, reports from national surveillance systems, and previously unpublished data from a large hospital in Kuwait. Such data must be viewed with caution. Differences between countries arise not only from genuine differences in prevalence, but also from differences in sampling strategies, laboratory processing, and standards for defining a "resistant" strain. Moreover, within-country comparisons across time are biased by measurement error, particularly for small samples. However, analysis of the currently available data does yield some evidence and may help to raise awareness and efforts to improve the data and methods for addressing the problem.

Our primary measure is the prevalence of resistance by a specific bacterium to a specific drug. The prevalence is calculated as the number of resistant isolates divided by the number of total isolates collected, multiplied by 100. We compute growth rates of resistance to specific bacteria

using standard year-on-year growth calculations. Where appropriate, we smooth variance in small-sample data series by using three-year running averages.

We also develop methods to aggregate specific "bug-drug" data to summarize the resistance pattern for each country. These measures weight resistance rates by (1) the isolation frequency for each bacterium (that is, the proportion of a particular bacterium among all bacteria studied); and, where possible, by (2) the proportion of resistant cases hospital- versus community-acquired; and (3) the frequency with which each drug is used to treat infections caused by each bacterium. (For most calculations, measure (3) is not available.) Finally, we compare and contrast each country's resistance experience and, using the subset of data comparable across the three countries, examine correlations in patterns of resistance.

These methods represent preliminary steps to gauge whether patterns of antibiotic resistance converge over time amongst countries that currently have little popula-



Source: CEIC Data Inc

Figure 1

Travel to and from China has increased tremendously over the past decade.

Table 1: Resistance prevalence of ten common bacteria to Ciprofloxacin in China, 1994–2000

											unit: %
Rank	Bacter.	1994	1995	1996	1997	1998	1999	2000	Average Resistance*	Average Growth Rate*	
1	Escherichia coli (ECO)	53	49	60	61	60	63	62	59	3	
2	Pseudomonas aeruginosa (PAE)	9	10	7	18	13	17	18	13	17	
3	Klebsiella pneumoniae (KPN)	2	4	7	8	14	17	18	10	40	
4	Staphylococci epidermidis (SEP)	22	33	34	35	41	40	46	36	9	
5	Staphylococci aureus (SAU)	MRS A**	47	65	74	88	83	78	76	76	7
		MSS A**	8	18	10	5	8	20	14	11	8
6	Enterococcus faecalis (EFA)	25	34	28	34	32	45	45	34	9	
7	Enterobacter cloacae (ECL)	12	9	13	14	22	31	30	18	26	
8	Acinetobacter baumannii (ABA)	7	7	19	20	23	31	37	20	29	
9	Citrobacter freundii (CFR)	10	21	20	17	22	26	26	20	10	
10	Proteus mirabilis (PMI)	8	2	13	2	5	14	12	7	10	
	Mea								28	15	
	n										
	Med								20	10	
	ian										

* Based on three-year running averages.

** Staphylococci aureus (SAU) is further grouped as methicillin susceptible staphylococci aureus (MSSA) and methicillin resistant staphylococci aureus (MRSA).

tion interchange. Future research would benefit from better surveillance of resistance, more comparable data reporting, data on antibiotic utilization, and further methodological advances in clinically- and policy-relevant aggregation of "bug-drug" data.

Results

China

In 1988, the World Health Organization West Pacific Regional Office set up two antimicrobial resistance surveillance centers in Beijing and Shanghai. Meanwhile, China's Ministry of Health also established the China Nosocomial Infection Surveillance (CNIS) program, which monitors hospital-acquired infections. Unfortunately, most of the surveillance programs in China focus on urban hospitals. We lack data on urban communities and for the rural majority. Nevertheless, the available data allows us to piece together a picture of the extent of antimicrobial resistance in the most populous country in the world.

To examine AMR development in China, we use annual data from a seven-year (1994–2000) study by China's National Center for Antimicrobial Resistance, which reports resistance levels of ten most prevalent bacteria to a common antibiotic, ciprofloxacin (Table 1) [25]. With small sample sizes, the annual measured percentage of isolates found to be resistant varies considerably; to smooth the random variation attributable to small sample size, we use three-year running averages. Some bacte-

ria such as ECO and MRSA have high proportions (60–80%) of resistant strains, whereas the prevalence of resistant strains for others such as PMI is quite low. Almost all but MSSA and PMI have shown considerable growth in resistance over the study period, resulting in an average annual growth rate of about 15%.

Another series of studies by the China Bacterial Resistance Surveillance Study Group focused on resistance prevalence among different patient types, i.e. those with hospital-acquired infections (HAI) versus community-acquired infections (CAI) [26,27]. We construct two measures to compare HAI and CAI resistance prevalence. First, by aggregating the seven bacteria, we get a measure γ indexed on the nineteen drugs. γ is calculated by multiplying the resistance rate of each bacterium by its isolation frequency and proportion among HAI (or CAI) infections, and then summing across bacteria. The measure is reported in the last two columns of Table 2 and graphed in Figure 2. Second, by aggregating the drugs, we obtain a measure indexed on bacteria. However, because we lack data on how often each drug is used, the best we can do is report the simple average for all drugs (implicitly assuming each drug is used with equal frequency). We name this measure Mean Resistance, shown in the last row in Table 2 and graphed in Figure 3.

Both measures reinforce the finding that infections acquired in a hospital are often more drug resistant than other (community-acquired) infections. For the seven

Table 2: Resistance patterns of the seven most common bacteria for Hospital-acquired Infections (HAI) and Community-acquired Infections (CAI), China 2001

Antibiotic(s)	unit: %															
	SAU (n = 176)		SEP (n = 84)		ECO (n = 308)		ECL (n = 78)		PAE (n = 232)		KPN (n = 215)		ABA (n = 191)		γ	
	HAI (37)	CAI (139)	HAI (14)	CAI (70)	HAI (44)	CAI (264)	HAI (27)	CAI (51)	HAI (95)	CAI (137)	HAI (48)	CAI (167)	HAI (46)	CAI (145)	HAI γ_H	CAI γ_C
Methicillin	89	30	43	27	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	11	5
Ampicillin	100	82	86	67	89	80	100	90	n/a	n/a	54	66	n/a	n/a	38	35
Amoxicillin	89	27	29	6	84	81	100	94	n/a	n/a	90	95	48	50	38	31
Ceftizoxime	87	28	14	7	32	25	96	86	n/a	n/a	33	26	96	92	24	16
Cefaclor	87	31	21	10	32	26	89	78	n/a	n/a	33	25	65	57	23	15
Cefuroxime	89	29	22	4	32	25	74	47	n/a	n/a	29	23	57	41	22	12
Cefprozil.	87	26	21	4	34	25	78	61	n/a	n/a	33	23	94	86	24	15
Ceftazidime	92	37	50	13	5	7	59	28	11	14	21	4	30	15	19	8
Cefotaxime	84	28	21	6	0	7	44	26	41	26	4	5	28	16	15	8
Ceftriaxone	89	28	21	3	9	8	48	29	40	25	6	5	33	15	18	8
Imipenem	76	21	21	1	2	0	0	2	2	3	0	1	2	1	8	2
Meropenem	78	21	14	1	2	0	0	0	2	2	0	1	2	2	8	2
Ciprofloxacin	87	35	36	30	75	53	63	33	26	13	19	14	26	17	29	18
Ofloxacin	78	30	36	30	75	55	59	31	17	15	15	14	22	17	27	18
Levofloxacin	46	7	29	10	68	52	33	20	22	15	10	11	13	12	21	13
Sparfloxacin	89	39	50	40	75	56	63	33	43	31	25	16	15	14	32	21
Moxifloxacin	5	2	14	3	64	43	22	18	43	27	4	8	13	15	17	12
Gatifloxacin	30	1	14	4	36	25	7	6	23	17	6	6	15	14	13	7
Gentamicin	87	31	36	21	43	38	30	24	37	29	27	16	35	21	25	16
Mean Resistance	77	28	30	15	42	34	54	39	26	18	23	20	35	28		




Figure 2 Hospital-acquired infections (HAI) are more resistant than community-acquired infections (CAI) to a wide range of antibiotics in China.

bacteria, the mean resistance rate of HAI is on average 1.5 times that of CAI in China. For the nineteen drugs, the aggregate measure of resistance for HAI, γ_H , is on average 1.9 times that for CAI, γ_C . This pattern is most extreme for infections caused by SAU, where resistance of HAI is two- to three- times that of CAI, depending on which measure is used. (T-tests of the difference between two groups indicate a p-value of less than 0.01 for the γ 's and less than 0.09 for the mean resistance). Moreover, the prevalence of drug resistance for both kinds of infections is quite high. Mean resistance of HAI is 41% and that of CAI is 28%.

United States

Fairly comprehensive data on resistance trends in the U.S. come from the National Nosocomial Infections Surveillance System (NNIS) for hospital-based resistance, and the U.S. Active Bacterial Core Surveillance (ABC) project, which surveys a population of 16 million to 25 million community residents in 9 states each year [28-30]. We use data from an ABC program that surveys *Streptococcus pneu-*

moniae (SPN) from 1997 to 2002 to examine prevalence and trends (Table 3). The average growth rate of resistance for this bacterium was 8%, lower than the 15% number for China. Interestingly, unlike the upward resistance trend in China, SPN resistance declined in the last two years of the study period in the US, following an initial rise. Such data should not be interpreted to mean that actual prevalence is permanently declining, since measurement issues engender considerable year-to-year variation in the sample prevalence.

The US NNIS program provides data for inpatients and outpatients. Further, among inpatients, the NNIS differentiates between those in and not in the ICU. For almost every bug-drug pair, resistance prevalence is highest among ICU patients, followed by non-ICU inpatients, with the lowest prevalence among outpatients (Table 4 and Figure 4). This pattern seems consistent with clinical reality, since patients in ICUs are more likely to have a weak immune system, either because of prolonged treat-




Figure 3
The Seven most common bacteria show higher resistance among hospital-acquired infections (HAI) than community-acquired infections (CAI) in China.

ment or their own compromised conditions; moreover, many are catheterized, offering a conduit for bacteria.

for hospital-acquired infections is 41% and that for community-acquired infections is 28%.

Compared with China, the U.S. exhibits more moderate differences in resistance prevalence among different patients. The average prevalence of resistance for ICU, other inpatients, and outpatients in the U.S. are 20%, 17% and 13%, respectively; in China, average resistance

Pooling all patients together (Table 5), we find the prevalence of resistance and its growth to be 17% and 7% respectively, consistent with our previous observation that the U.S. seems to have both lower resistance prevalence and less dramatic increase in resistance than China does.

Table 3: Non-susceptibilities of *Streptococcus pneumoniae* (SPN) in U.S. communities, 1997–2002

Unit: %								
Antibiotic	1997	1998	1999	2000	2001	2002	Average Resistance	Average Growth Rate
Penicillin	25	24	27	28	26	21	25	2
Cefotaxime	13	14	17	18	16	12	15	-1
Erythromycin	15	15	21	22	19	17	18	4
TMP/Sulfa	29	29	32	32	30	25	30	-3
Levofloxacin	n/a	0.2	0.2	0.3	0.7	0.5	0.4	39
Vancomycin	0	0	0	0	0	0	18	8

Table 4: Resistance prevalence for selected drug-bug pairs by patient type, U.S. 1999–2002

unit: %				
Pair	Bacterium (resistant to) → drug	ICU patients	non-ICU inpatients	Outpatients
A	PAE → Ciprofloxacin/ofloxacin	32	25	23
B	PAE → Levofloxacin	37	28	25
C	PAE → Imipenem	18	12	9
D	PAE → Ceftazidime	13	8	5
E	PAE → Piperacillin	16	11	6
F	SAU → Methicillin	47	38	23
G	Enterococcus spp → Vancomycin	13	11	4
H	ECO → Cef3*	1	1	0
I	ECO → Quinolone**	5	4	2
J	KPN → Cef3	6	5	2
K	Enterobacter spp → Cef3	26	21	10
L	Enterobacter spp → Carbapenum	1	1	1
M	CNS → Methicillin	75	63	46
N	Pneumococcus → Penicillin	18	17	17
O	Pneumococcus → Cef3	7	8	6
	Mean	21	17	12

*Cef3 (3rd generation cephalosporin) = ceftazidime, cefotaxime or ceftriaxone;

**Quinolone = ciprofloxacin, ofloxacin or levofloxacin.

Kuwait

There is considerably less detailed data on antibiotic resistance for Kuwait than for China or the U.S. We gath-

ered data on antimicrobial resistance among isolates of eight different bacterial diseases over the most recent five years. The data is based on surveillance from a single large

Table 5: Resistance prevalence of eight common bacteria, U.S. (all patients pooled), 1999–2002

unit: %							
Bacterium	Resistant to antibiotic(s)	1999	2000	2001	2002	Average Resistance	Average Growth Rate
PAE	Ciprofloxacin/ofloxacin	23	25	28	29	26	8
	Levofloxacin	29	30	31	30	30	1
	Imipenem	12	12	15	13	13	4
	Ceftazidime	8	8	9	9	9	4
	Piperacillin	10	10	11	12	11	6
SAU (MRSA)	Methicillin	32	35	38	39	36	7
Enterococcus spp	Vancomycin	11	8	10	10	10	-1
ECO	Cef3	1	1	1	1	1	0
	Quinolone	2	3	4	5	4	36
KPN	Cef3	4	4	4	5	4	8
Enterobacter spp	Cef3	19	19	18	19	19	0
CNS	Carbapenum	1	1	1	1	1	0
	Methicillin	60	61	62	63	62	2
Pneumococcus spp	Penicillin	14	16	19	19	17	11
	Cef3	5	8	7	7	7	16
	Mean:					17	7




Figure 4

ICU patients have the highest resistance rates in selected drug-bug pairs, followed by non-ICU inpatients and outpatients, U.S. 1999–2002.

teaching hospital, Mubarak Al-Kabeer Hospital, which serves a catchment area representing about 60% of Kuwait's population. We report that data for the first time here and in a companion paper [31] (see Tables 6, 7, 8, 9). The average resistance level for all surveyed bacteria was about 27% from 1999 to 2003 (Table 10), higher than the 17% for the U.S. and about the same as the 28% China. As for the other two countries, resistance appears to be growing in Kuwait.

Discussion: Comparing antibiotic resistance in China, the U.S. and Kuwait

In China, resistance rates exhibit a clear and rapid upward trend. In the U.S., resistance currently appears to grow at a more leisurely pace. Kuwait seems to be somewhere in between. It is important to note that the pace of growth may depend on whether resistance to a particular antibiotic has reached a potential equilibrium. As shown in the previous data, the 3% resistance growth rate of ECO against Ciprofloxacin in China (Table 1), is considerably

lower than it is in the other two countries against similar quinolone drugs (Table 5 and Table 10). This is probably because ECO resistance may have virtually reached equilibrium in China by the beginning of the study period; hence it didn't grow much in subsequent years.

That resistance does not grow without bound highlights the importance of comparing the current prevalence of resistance in the three countries. After all, the prevalence of resistance reflects the risk of a drug-resistant infection for any given patient. A low rate of growth is small consolation if patients already face a high baseline risk of acquiring an expensive, debilitating and even potentially untreatable "superbug" infection.

The prevalence of resistance also substantially differs across countries, although as noted previously, surveillance data is far from ideal in capturing the true scope of the problem. As shown in Table 11, using the data currently available, China has far higher prevalence of resist-

Table 6: Resistance trend in isolates of *Salmonella* spp. over 5 years in Kuwait

Antibiotic	Percentage (%) of resistant isolates in:				
	1999 (n = 216)	2000 (n = 215)	2001 (n = 129)	2002 (n = 167)	2003 (n = 165)
Amikacin	0	0	0	0	0
Ampicillin	6	12	7	25	26
Amoxicillin-clavulanate	5	10	7	2	0
Cefotaxime	0	1	0	1	0
Ceftriaxone	0	1	0	2	0
Cefuroxime	1	1	0	27	41
Cephalexin	2	10	37	57	50
Chloramphenicol	8	21	0	18	18
Ciprofloxacin	0	0	14	10	16
TMP/SMX	8	8	10	20	20
Gentamicin	6	1	0	42	42
Imipenem	0	0	0	0	0
Meropenem	0	0	0	0	0
Piperacillin	6	13	13	23	25
Piperacillin/tazobactam	0	0	0	0	0

No ESBL-producing strain has been isolated so far

ance for all the bacteria studied. For example, in China resistance of SPN to one of the oldest antibiotics, erythromycin, reaches 73%, while the figure for Kuwait is only 23%. A challenge for the U.S. is the exceptionally high level of Vancomycin-Resistant *Enterococcus* spp (VRE). In the U.S., 53% of *Shigella* spp are resistant to Trimethoprim/Sulfamethoxazole (TMP/SMX), in contrast to 0% in both of the other countries. These examples suggest that severity of resistance may be correlated with volume of usage. Vancomycin is less affordable in both China and Kuwait, presumably resulting in less usage in those countries.

Table 12 compares the three countries with Japan and Taiwan regarding prevalence of three important drug-resist-

ant bacteria: MRSA, penicillin resistant SPN (PRSP) and vancomycin-resistant *Enterococcus* spp (VRE) [32-34]. Interestingly, each country has its own most problematic resistance culprit. For China, MRSA is the biggest threat, where resistance among hospital-acquired infections reaches almost 90%, the highest among the five countries. For the U.S., VRE is high. VRE growth in the U.S. can be traced to the late 1980s and is probably among the highest in the world. For Kuwait, PRSP is considerable. Both Taiwan and Japan are also troubled by at least one of these three resistant bacteria.

Resistance correlations

How similar or different are resistance patterns in different countries? Does transmission travel across national

Table 7: Resistance trend in isolates of *Streptococcus pneumoniae* over a 5-year period in Kuwait

Antibiotics	Percentage (%) of resistant isolates in:				
	1999 (n = 78)	2000 (n = 61)	2001 (n = 73)	2002 (n = 66)	2003 (n = 90)
Cefotaxime	0	0	4	5	6
Ceftriaxone	0	0	3	5	4
Cefuroxime	0	0	8	9	41
Cephalexin	0	0	NT	NT	NT
Chloramphenicol	3	5	25	5	0
Erythromycin	16	20	23	26	30
Imipenem	0	0	0	0	0
Penicillin	32	38	46	52	54
Teicoplanin	0	0	0	0	0
Vancomycin	0	0	0	0	0

NT = not tested

Table 8: Percentage of *Enterococcus* species resistant to often-tested antibiotics over 5 years in Kuwait

Antibiotic	Percentage (%) of resistant isolates in:				
	1999 (n = 370)	2000 (n = 335)	2001 (n = 322)	2002 (n = 248)	2003 (n = 212)
Ampicillin	1	1	3	2	0
Erythromycin	59	78	77	75	92
Gentamicin	26	36	61	52	98
Nitrofurantoin	2	2	2	36	86
Norfloxacin	36	47	47	NT	NT
Penicillin	16	38	35	53	85
Teicoplanin	0	0	0	1	0
Vancomycin	1	0	0	2	0

NT = not tested

borders as humans do? If so, do countries' resistance patterns converge? To begin to examine this issue, we construct coefficients of resistance correlation among China, U.S. and Kuwait. We rank resistance rates for 24 bug-drug pairs and define perfect correlation as each bug-drug pair displaying the same resistance rank. Perfect negative correlation exists if the ranks in two countries go in precisely the opposite order. Table 13 reports the correlation coefficient for each pair of countries. The statistic by definition is bounded between -1 and 1, where -1 means perfect disagreement while 1 means perfect agreement. Thus the bigger the statistic, the more correlated two countries' resistance patterns are.

Of course, methods for aggregation and comparing patterns of resistance across countries and over time should be improved, and applied more fruitfully with better data from increased local and global surveillance. But even this preliminary analysis reveals some interesting patterns. For

example, resistance rates in China are much more strongly correlated with those in Kuwait than those in the U.S. This correlation pattern suggests that at least in the short run, resistance in a country is more likely to be determined by endogenous factors (such as strictness of practices for prescribing drugs). In the long run, the frequency and magnitude of contacts among nations with different resistance problems is likely to be critical. Because Kuwait and China are relatively isolated countries, it is less surprising that their antibiotic resistance problems show domestic characters. However, as we expect them to be opening more to the world, particularly China, the problem may worsen when these countries can increasingly export and import antibiotic resistance. China, the most populous country in the world and an economy with the highest growth, is particularly likely to exacerbate the problem. As illustrated in Figure 1, the number of Chinese departures to overseas destinations has been growing at increasing rates in the

Table 9: Percentage of *Staphylococcus aureus* resistant to often-tested antibiotics over 5 years in Kuwait

Antibiotic	Percentage (%) of resistant isolates in:				
	1999 (n = 648)	2000 (n = 595)	2001 (n = 484)	2002 (n = 420)	2003 (n = 286)
Ampicillin	96	100	98	96	98
Amoxicillin-clavulanic acid	6	33	27	22	29
Cephalexin	33	30	25	36	34
Ciprofloxacin	10	35	30	45	50
Clindamycin	18	24	20	20	27
Cloxacillin	23	24	9	22	17
Erythromycin	38	34	26	28	27
Fusidic acid	NA	20	19	64	27
Gentamicin	25	21	16	24	27
Methicillin	23	24	9	22	17
Penicillin	95	95	99	96	99
Teicoplanin	0	0	0	0	0
TMP/SMX	24	27	31	18	94
Vancomycin	0	0	0	0	0

Table 10: Average Resistance Levels of Major Bacteria in Kuwait, 1999–2003

unit: %										
	ECO	KPN	PAE	SPN	Shigella spp.	Salmonella spp.	Enterococcus spp.	SAU	Average Resistance	Average Growth
Average Annual Resistance	13	8	5	31	45	65	37	8	27	17

past decade and continues to show upward momentum in recent years.

No doubt, there are also complex interactions with levels of economic well-being. Drugs become more affordable as countries become richer, but they are likely to be given out more carefully, particularly since concerns about resistance also increase. The critical question for policy is

whether countries can control their own resistance problems, and also avoid importing the problem from abroad.

Conclusion

We have outlined the nature of the antimicrobial resistance problem as an important health and cost issue for three quite disparate nations, and by inference for a broad swath of the world's population. Surprisingly, this issue

Table 11: Resistance rates in China, U.S. and Kuwait, hospital surveillance data for 2001

From Tables 1,2,3,8 and 9; Unit: %						
Bacterium(a)	Antibiotic(s)	Pair	China	U.S.	Kuwait	
SAU	Methicillin	A	37	38	9	
SPN	Erythromycin	B	73	19	23	
Enterococcus spp	Cefotaxime	C	0	16	4	
	Vancomycin	D	4	10	0	
	ECO	Ceftazidime	E	9	1*	5
	Cefotaxime	F	18	1*	1	
PAE	Ceftriaxone	G	21	1*	1	
	Ciprofloxacin/Ofloxacin	H	56	3	26	
PAE	Ceftazidime	I	17	9	27	
	Ciprofloxacin/Ofloxacin	J	27	28	31	
KPN	Ceftazidime	K	9	4*	14	
	Cefotaxime	L	17	4*	13	
	Ceftriaxone	M	20	4*	13	
	Ciprofloxacin	N	18	12**[27]	18	
Salmonella spp	Amoxicillin-clavulanate	O	10	4	7	
	Ceftriaxone	P	5	1	0	
	Ciprofloxacin	Q	0	0.4	10	
	TMP/SMX***	R	0	3	0	
Shigella spp	Gentamicin	S	10	2	0	
	Amoxicillin-clavulanate	T	35	2	20	
	Ceftriaxone	U	6	0	0	
	Ciprofloxacin	V	6	0	0	
	TMP/SMX	W	0	53	0	
	Gentamicin	X	18	0.2	0	
Average			17	7	9	

* The original U.S. NNIS reported resistance rates to either one of the Cef3 drugs, i.e. ceftazidime, cefotaxime or ceftriaxone. We assume the same rates for each drug.

** Based on surveillance of ICU patients

*** TMP/SMX = Trimethoprim/Sulfamethoxazole

Table 12: MRSA, PRSP & VRE in Selected Countries

Unit: %			
	MRSA (HAI only)	PRSP	VRE
China	89 (2001)	27 (2001)	0 (2001)
U.S.	16 (2001)	26 (2001)	0.3 (1989), 8 (1993), 12.8 (2001) in ICU
Kuwait	9 (2001)	46 (2001)	0 (2001)
Japan [33]	60–80% (1999)	11–40 (1999)	n/a
Taiwan [34]	n/a	69 (2000)	2 (2000)

virtually never receives prominent attention at the national or international level, despite its scope and potentially devastating impact on global public health in the coming decades.

We examined antimicrobial resistance data for China, Kuwait, and the United States. In each country, we looked at specific infectious agents and their resistance to particular antibiotics or other antimicrobials. Though an upward trend of resistance is found broadly, the patterns of correlation between countries' resistance rates suggest predominantly independent profiles. But we would expect greater convergence as globalization increases contacts between different nations' populations, raising ques-

tions about how to coordinate an effective international response [35].

Future research should develop better methods of data aggregation, explore the patterns of drug resistance across more countries, analyze the determinants of transmission of drug resistance across national boundaries, and assess how those determinants are progressing. Individuals everywhere would benefit if far greater attention were paid to the problem of antimicrobial resistance.

Competing interests

The author(s) declare that they have no competing interests.

Table 13: Ranks of resistance rates in China, U.S. and Kuwait, 2001(Rank correlations at bottom of table)

Bacterium(a)	Antibiotic(s)	China	U.S.	Kuwait	
SAU	Methicillin	3	2	11	
SPN	Erythromycin	1	4	4	
Enterococcus spp	Cefotaxime	21	5	14	
	Vancomycin	20	7	17	
	ECO	Ceftazidime	15	17	13
	Cefotaxime	8	18	15	
PAE	Ceftriaxone	6	19	16	
	Ciprofloxacin/Ofloxacin	2	13	3	
	Ceftazidime	11	8	2	
KPN	Ciprofloxacin/Ofloxacin	5	3	1	
	Ceftazidime	16	9	7	
Salmonella spp	Cefotaxime	12	10	8	
	Ceftriaxone	7	11	9	
	Ciprofloxacin	9	6	6	
	Amoxicillin-clavulanate	13	12	12	
	Ceftriaxone	19	20	18	
Shigella spp	Ciprofloxacin	22	21	10	
	TMP/SMX	23	14	19	
	Gentamicin	14	15	20	
	Amoxicillin-clavulanate	4	16	5	
	Ceftriaxone	17	23	21	
	Ciprofloxacin	18	24	22	
	TMP/SMX	24	1	23	
	Gentamicin	10	22	24	
Correlation Coefficients		CHN_US: 0.18	US_KW: 0.46	CHN_KW: 0.60	

Authors' contributions

RFZ assembled the data, carried out the analysis and drafted the manuscript. KE and RJZ conceived of the study, participated in its design and coordination, and helped to draft the manuscript. VR provided the Kuwait data and helped to draft the manuscript. All authors read and approved the manuscript.

Acknowledgements

The authors gratefully acknowledge financial support from the Kuwait Foundation for the Advancement of Sciences through the John F. Kennedy School of Government at Harvard University.

References

- Kimball AM, Arima Y, Hodges RH: **Trade related infections: farther, faster, quieter.** *Globalization and Health* 2005, **1**:3.
- Hodges RH, Kimball AM: **The global diet: trade and novel infections.** *Globalization and Health* 2005, **1**:4.
- Wilson KH, Blichington RB: **Human colonic biota studied by ribosomal DNA sequence analysis.** *Appl Environ Microbiol* **62**(7):2273-2278.
- Institute of Medicine: **Emerging infections: microbial threats to health in the United States.** National Academy Press 1994.
- Wilson KH, Blichington RB: **Human colonic biota studied by ribosomal DNA sequence analysis.** *Appl Environ Microbiol* **62**(7):2273-8.
- Davies J: **Bacteria on the rampage.** *Nature* 1996, **383**:219-220.
- Field HJ, Coen DM: **Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene.** *J Virol* 1986, **60**(1):286-289.
- Muder RR, Brennen C, Wagener MM, et al.: **Temporal shifts in traits of *Vibrio cholerae* strains isolated from hospitalized patients in Calcutta: a 3-year (1993-1995) analysis.** *J Clin Microbiol* 1996, **34**:2537-2543.
- Bisognano C, et al.: **Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant *Staphylococcus aureus* exposed to subinhibitory levels of ciprofloxacin.** *Antimicrob Agents Chemother* 1997, **41**(5):906-913.
- World Health Organization: **WHO Global Strategy for Containment of Antimicrobial Resistance.** Geneva 2001.
- Arason VA, Kristinsson KG, et al.: **Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study.** *BMJ* 1996, **313**:387-91.
- Seppala H, Klaukka T, et al.: **The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance.** *N Engl J Med* 1997, **337**:441-6.
- Levy SB, Fitzgerald GB, Macone AB: **Spread of Antibiotic-Resistant Plasmids from Chicken to Chicken and from Chicken to Man.** *Nature* 1976, **260**(5546):40-42.
- Levy SB, Fitzgerald GB, Macone AB: **Changes in Intestinal Flora of Farm Personnel after Introduction of a Tetracycline-Supplemented Feed on a Farm.** *N Engl J Med* 1976, **295**:583-588.
- Witte W: **Selective pressure by antibiotic use in livestock.** *Int J Antimicrob Agents* 2000, **16**(Suppl 1):S19-24. Review
- Breathnach AS, de Ruiter A, Holdsworth GM, et al.: **An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital.** *J Hosp Infect* 1998, **39**(2):111-117.
- Hannan MM, Azadian BS, Gazzard BG, et al.: **Hospital infection control in an era of HIV infection and multi-drug resistant tuberculosis.** *J Hosp Infect* 2000, **44**(1):5-11.
- Martin MA: **Methicillin-resistant *Staphylococcus aureus*: the persistent resistant nosocomial pathogen.** *Curr Clin Top Infect Dis* 1994, **14**:170-191.
- Wang F, Zhu D, et al.: **Surveillance of bacterial resistance in Shanghai.** *Chin J Infect Chemother* 2002, **2**(1):1-9.
- Cox RA, Conquest C, Malaghan C, et al.: **A major outbreak of methicillin-resistant *Staphylococcus aureus* caused by new phage-type (EMRSA-16).** *J Hosp Infect* 1995, **29**:87-106.
- Astagneau P, et al.: **Cost of antimicrobial treatment for nosocomial infections based on a French prevalence survey.** *J Hosp Infect* 1999, **42**:303-312.
- Haley RW, Morgan WM, Culver DH, et al.: **Update from the SENIC project. Hospital infection control: Recent progress and opportunities under prospective payment.** *Am J Infect Control* 1985, **13**:97-108.
- Duckworth GJ: **Diagnosis and management of methicillin-resistant *Staphylococcus aureus* infection.** *British Medical Journal* 1993, **307**:1049-1052.
- Tsiodras S, Gold H, et al.: **Linezolid resistance in a clinical isolate of *Staphylococcus aureus*.** *Lancet* 2001, **358**:207-208.
- Chen H, Ma Y, National Antimicrobial Resistance Surveillance Center, et al.: **The Changing Patterns of Ciprofloxacin Resistant Bacteria Strains Isolated from Fifty Hospitals in China from 1994 to 2000.** *Chin J Infect Chemotherapy* 2002, **2**(4):43-45.
- Li J, Li G, Wang J: **Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections.** *Natl Med J China* 2003, **83**(5):365-374. (in Chinese)
- Li J, Li G, Wang J: **Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections.** *Natl Med J China* 2003, **83**(12):1035-1045. (in Chinese)
- National Nosocomial Infections Surveillance System 2001 [http://www.cdc.gov/ncidod/hip/SURVEILL/nnis_pubs.HTM]. report
- National Antimicrobial Resistance Monitoring System for Enteric Bacteria 2002 [<http://www.cdc.gov/narms/>]. report
- Active Bacterial Core Surveillance 2001 [<http://www.cdc.gov/ncidod/dbmd/abcs/reports.htm>]. report
- Eggleston KE, Rotimi V, Ghayda A, Zhang R, Zeckhauser RJ: **An economic analysis of antimicrobial resistance in Kuwait.** *J Antimicrobial Chemotherapy*. Forthcoming
- Neuhauser MM: **Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.** *JAMA* 2003, **289**(7):885-888.
- Sun Z: **Antimicrobial resistance and clinical interventions.** *Adverse Drug Reaction J* 2003, **3**:151-155.
- McDonald LC, Lauderdale T, et al.: **The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme 2000.** *Int J Antimicrob Agents* 2004, **23**(4):362-370.
- Fidler DP: **Globalization, international law, and emerging infectious diseases.** *Emerg Infect Dis* 1996, **2**(2):77-84.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

